<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Vitiligo: Pathogenesis, clinical features, and diagnosis</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Vitiligo: Pathogenesis, clinical features, and diagnosis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Vitiligo: Pathogenesis, clinical features, and diagnosis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Pearl E Grimes, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hensin Tsao, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew F Alexis, MD, MPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rosamaria Corona, MD, DSc</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 26, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1838574464"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Vitiligo is a relatively common acquired disorder of pigmentation characterized by the development of well-defined, depigmented macules on the skin. Biopsies of lesional skin reveal a loss of epidermal melanocytes [<a href="#rid1">1-4</a>]. Lesions may occur in a localized or generalized distribution and may coalesce into large, depigmented areas. Given the contrast between the white areas and normal skin, the disease is most disfiguring in individuals with darkly pigmented skin and has a profound impact on the quality of life of both children and adults [<a href="#rid5">5,6</a>]. Patients with vitiligo often experience stigmatization, social isolation, and low self-esteem [<a href="#rid7">7-10</a>].</p><p>This topic will review the pathogenesis, classification, clinical manifestations, and diagnosis of vitiligo. The management and prognosis of vitiligo are discussed separately. Other pigmentation disorders are also discussed separately.</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/106619.html" rel="external">"Vitiligo: Management and prognosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/103736.html" rel="external">"Acquired hypopigmentation disorders other than vitiligo"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/89268.html" rel="external">"Acquired hyperpigmentation disorders"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/6621.html" rel="external">"Melasma: Management"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/95847.html" rel="external">"Postinflammatory hyperpigmentation"</a>.)</p><p></p><p class="headingAnchor" id="H1838574470"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Vitiligo is the most frequent cause of skin depigmentation [<a href="#rid2">2-4,11</a>]. Estimated prevalence rates range from 0.1 to 2 percent in both adults and children [<a href="#rid12">12-17</a>]. In a population-based, online survey of over 40,000 adults in the United States, the estimated point prevalence of vitiligo was 1.38 percent (self-reported) and 0.76 percent (clinician adjudicated) [<a href="#rid18">18</a>].</p><p>In an analysis of electronic health records across four United States census regions, the estimated age- and sex-adjusted overall incidence rate of vitiligo diagnosed between 2015 and 2019 was 22.6 per 100,000 per year (95% CI 21.5-23.8 per 100,000 per year) [<a href="#rid19">19</a>]. In the United Kingdom, the estimated age and sex standardized incidence of vitiligo between 2017 and 2019 was 18.4 per 100,000 person-years [<a href="#rid20">20</a>].</p><p>Vitiligo equally affects males and females, without racial, ethnic, or socioeconomic predilections [<a href="#rid13">13</a>]. It may appear at any age from early childhood to late adulthood, with peak incidences in the second and third decade of life [<a href="#rid21">21</a>]. Approximately one-third of patients with vitiligo are children, and 70 to 80 percent of adult patients develop vitiligo prior to age 30 years [<a href="#rid2">2</a>].</p><p class="headingAnchor" id="H14676582"><span class="h1">ETIOLOGY</span><span class="headingEndMark"> — </span>The etiology of vitiligo is unknown. Patients commonly attribute the onset of their disease to specific triggering events such as physical injury or illness, sunburn, emotional stress, or pregnancy, but there are no data supporting a causative role for these factors. The frequency of comorbid autoimmune diseases is significantly elevated in patients with vitiligo and in their first-degree relatives, suggesting an autoimmune etiology for this disorder [<a href="#rid13">13</a>].</p><p>Recipients of hematopoietic stem cell transplantation (HSCT) appear to have an increased risk of developing vitiligo [<a href="#rid22">22,23</a>]. In a Korean nationwide population study including 2747 HSCT recipients and 8241 controls, HSCT recipients had a three-fold increased risk of having vitiligo compared with controls (odds ratio 3.13, 95% CI 1.86-5.27) [<a href="#rid24">24</a>]. Allogeneic HSCT and bone marrow-sourced stem cells were independently associated with the development of vitiligo after HSCT. The pathogenetic mechanisms underlying the development of vitiligo in HSCT recipients are unclear. They may include adoptive transfer of vitiligo from donor [<a href="#rid25">25</a>], immunosuppression associated with preparative regimens, or chronic graft-versus-host disease [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H1838574476"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Multiple theories have been proposed for melanocyte destruction in vitiligo. These include genetic, autoimmune, neural, biochemical, oxidative stress, viral infection, and melanocyte detachment mechanisms. Although the autoimmune and oxidative stress theories are best supported by research data, none of the proposed theories are in themselves sufficient to explain the diverse vitiligo phenotypes [<a href="#rid3">3,27,28</a>]. The so-called "convergence theory" suggests that multiple mechanisms may contribute to the disappearance of melanocytes in vitiliginous skin and that vitiligo may indeed represent a disease spectrum [<a href="#rid29">29</a>].</p><p class="headingAnchor" id="H1838574482"><span class="h2">Genetics</span><span class="headingEndMark"> — </span>Family clustering of vitiligo suggests a genetic basis for the disease [<a href="#rid13">13,30</a>]. Genetic studies indicate a non-Mendelian, multifactorial, polygenic inheritance pattern [<a href="#rid31">31-33</a>]. Twenty-five to 50 percent of persons with vitiligo have affected relatives [<a href="#rid13">13,30</a>]. A survey conducted among 2624 patients with vitiligo from North America and the United Kingdom found a 6 percent prevalence of vitiligo in siblings of patients with vitiligo [<a href="#rid13">13</a>]. In this cohort, the concordance in monozygotic twins was only 23 percent, suggesting that nongenetic factors and/or environmental triggers play a role in the pathogenesis of the disease.</p><p>Genetic studies have identified approximately 36 susceptibility loci for nonsegmental vitiligo [<a href="#rid34">34</a>]. The majority of the susceptibility genes encode immunoregulatory proteins, whereas several encode melanocyte proteins. Multiple studies have also implicated human leukocyte antigen loci in vitiligo, including A2, DR4, DR7, DQ7, DR1, B13, DQW3, CW6, and A30 [<a href="#rid28">28,31,32,35,36</a>]. In genome-wide association studies, several genes with known associations with other autoimmune disorders were identified as potential susceptibility loci for generalized vitiligo, including <em>PTPN22</em>, <em>LPP</em>, <em>IL2RA</em>, <em>UBASH3A</em>, <em>C1QTNF6</em>, and genes encoding major histocompatibility complex (MHC) I and MHC II molecules [<a href="#rid16">16,21,27,28,37-40</a>].</p><p>However, there is significant genetic heterogeneity in different ethnic groups. A genome-wide linkage study performed in 71 White multiplex families with vitiligo from North America and the United Kingdom found highly significant linkage to the autoimmune disease susceptibility locus <em>AIS1</em> on chromosome 1p31, suggesting that <em>AIS1 </em>is a major susceptibility locus [<a href="#rid33">33</a>]. The corresponding gene was subsequently identified as <em>FOXD3</em> [<a href="#rid41">41</a>]. Genetic studies in Chinese families have shown linkage evidence to chromosome 4q13-q21 [<a href="#rid42">42</a>]. </p><p>Other candidate genes for vitiligo susceptibility include the catalase gene, vitiligo-associated protein 1 on chromosome 2p16, and the guanosine triphosphate cyclohydrolase I gene [<a href="#rid27">27,31,32</a>]. The <em>NALP1</em> gene on chromosome 17p13, encoding the NACHT leucine-rich repeat protein 1, a regulator of the innate immune system, has been linked to vitiligo-associated multiple autoimmune disease, a group of diseases including various combinations of vitiligo, autoimmune thyroid disease, and other autoimmune and autoinflammatory syndromes [<a href="#rid43">43</a>].</p><p class="headingAnchor" id="H963463807"><span class="h2">Autoimmunity</span><span class="headingEndMark"> — </span>Historically, vitiligo has been associated with several autoimmune diseases, including Hashimoto's thyroiditis, Graves' disease, type 1 diabetes mellitus, alopecia areata, pernicious anemia, rheumatoid arthritis, autoimmune polyglandular syndrome, and psoriasis [<a href="#rid21">21,28,44,45</a>]. A survey in North America and the United Kingdom found that approximately 20 percent of 2624 vitiligo probands had a history of autoimmune thyroid disease compared with 2 percent of the general population [<a href="#rid13">13</a>].</p><p>Many humoral and cell-mediated immune aberrations have been reported in patients with vitiligo, including an increased frequency of organ-specific autoantibodies, such as antithyroglobulin, antithyroid peroxidase, antiparietal cells, and antinuclear antibodies [<a href="#rid46">46,47</a>]. The presence of antibodies to surface and cytoplasmic melanocyte antigens in the sera of patients with vitiligo lends additional support to the autoimmune pathogenesis of this disease [<a href="#rid48">48-50</a>]. These antibodies can induce the destruction of melanocytes grown in culture by complement-mediated lysis and antibody-dependent cellular cytotoxicity [<a href="#rid48">48,49</a>]. In addition, melanocyte antibodies, when passively administered to nude mice grafted with human skin, have a destructive effect on melanocytes within the skin graft [<a href="#rid51">51</a>].</p><p>Studies also suggest that cytotoxic T lymphocytes may play a significant role in melanocyte destruction in vitiligo [<a href="#rid52">52</a>]. Numerous activated cytotoxic T lymphocytes have been reported in the perilesional area of the vitiliginous skin, often in apposition to disappearing melanocytes [<a href="#rid53">53</a>]. These infiltrating lymphocytes are predominantly cytotoxic CD8<sup>+</sup> lymphocytes that express the skin homing receptor cutaneous leucocyte-associated antigen receptor. Moreover, purified CD8<sup>+</sup> T cells isolated from lesional skin of patients with vitiligo can induce melanocyte apoptosis in autologous nonlesional skin explants [<a href="#rid54">54,55</a>].</p><p>Multiple cytokines have also been implicated in the destruction of melanocytes in vitiligo. Several studies have documented increased expression of tumor necrosis factor-alpha, interferon-gamma, interleukin (IL) 10, and IL-17 in lesional skin of patients [<a href="#rid3">3</a>]. Investigations suggest that the interferon gamma-induced chemokine CXCL-10 is a key mediator of melanocyte destruction [<a href="#rid56">56</a>].</p><p class="headingAnchor" id="H1838574488"><span class="h2">Melanocyte self-destruction hypothesis</span><span class="headingEndMark"> — </span>The self-destruction hypothesis proposes that melanocytes may be destroyed from an intrinsic increased sensitivity to oxidative stress arising from toxic phenolic compounds formed during the synthesis of melanin [<a href="#rid57">57</a>]. This hypothesis is supported by the observation that a number of ubiquitous compounds containing catechols, phenols, and sulfhydryls (eg, industrial chemicals, cleaning agents, some hair dyes) can induce hypopigmentation, depigmentation, or both. Possible mechanisms for altered pigment production by these compounds include melanocyte destruction via free-radical formation, inhibition of tyrosinase activity, and interference with the production or transfer of melanosomes [<a href="#rid58">58</a>]. Additional data suggest that phenols can activate the unfolded protein response in melanocytes, causing induction of factor X-box binding protein 1, which leads to the production of IL-6 and IL-8 and recruitment of immune cells to the affected areas [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H3334777129"><span class="h2">Oxidative stress hypothesis</span><span class="headingEndMark"> — </span>Several studies suggest that oxidative stress may be the initial event in the destruction of melanocytes [<a href="#rid59">59,60</a>]. An imbalance of intracellular redox status and a significant depletion of enzymatic and nonenzymatic antioxidants have been demonstrated in the epidermis of patients with active vitiligo [<a href="#rid61">61</a>]. Low catalase and glutathione levels (but increased superoxide dismutase and xanthine oxidase levels) have also been found in the peripheral blood of patients with vitiligo [<a href="#rid58">58</a>].</p><p>Defective recycling of 6-tetrahydrobiopterin (6BH4), increased production of hydrogen peroxide, and decreased catalase levels have also been found in lesional skin of patients with vitiligo [<a href="#rid59">59,60,62</a>]. The altered tetrahydrobiopterin homeostasis may result in increased levels of toxic metabolites (eg, 6BH4 and 7-tetrahydrobiopterin) and hydrogen peroxide and reduced levels of catalase, a key enzyme involved in hydrogen peroxide removal, which may further contribute to cell death [<a href="#rid63">63</a>].</p><p>Oxidative stress may also contribute to melanocyte destruction in susceptible individuals via activation of the innate immune response [<a href="#rid2">2,3</a>]. Reactive oxygen species can act as danger signals and activate pattern recognition receptors to initiate inflammation, with local recruitment of innate immune cell populations, such as macrophages, natural killer cells, and inflammatory dendritic cells [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H1838574500"><span class="h2">Neural hypothesis</span><span class="headingEndMark"> — </span>The neural hypothesis posits that nerve endings situated near pigment cells may secrete a neurochemical mediator that is cytotoxic to the melanocytes [<a href="#rid28">28</a>]. This hypothesis is supported by the observation that the distribution of the depigmented areas in segmental vitiligo is related to dermatomes, even though the segments are almost never strictly dermatomal [<a href="#rid28">28,64</a>]. Moreover, vitiligo has been reported following neurologic disorders such as viral encephalitis, multiple sclerosis with Horner syndrome, and peripheral nerve injury [<a href="#rid28">28,65</a>]. Laboratory findings also support the neural hypothesis. Axon degeneration has been seen in dermal nerves of vitiliginous skin but not in dermal nerves of normal skin [<a href="#rid66">66</a>]. Immunohistochemistry studies of nerve endings in skin surrounding vitiligo lesions have shown abnormalities in the expression of nerve growth factors and neuropeptides [<a href="#rid67">67</a>]. Blood levels of certain neuropeptides are increased among patients with active vitiligo [<a href="#rid68">68,69</a>].</p><p class="headingAnchor" id="H1655559738"><span class="h2">Melanocytorrhagy hypothesis</span><span class="headingEndMark"> — </span>This theory proposes that melanocyte loss in vitiligo is secondary to chronic melanocyte detachment from the basement membrane. Causes include trauma, reactive oxygen species, autoimmune defects, and abnormal synthesis of extracellular matrix proteins leading to impaired cell adhesion [<a href="#rid57">57,70</a>].</p><p class="headingAnchor" id="H79502398"><span class="h1">CLINICAL FEATURES</span></p><p class="headingAnchor" id="H1089039858"><span class="h2">General features</span><span class="headingEndMark"> — </span>Vitiligo typically presents with asymptomatic depigmented macules and patches, milk or chalk white in color, that lack clinical signs of inflammation  (<a class="graphic graphic_picture graphicRef106463" href="/d/graphic/106463.html" rel="external">picture 1</a>). Severe sunburn, pregnancy, skin trauma, and/or emotional stress may precede the disease onset [<a href="#rid71">71</a>]. Lesions can appear at any age and anywhere on the body, with a predilection for the face and areas around the orifices, genitals, and hands. They vary in size from a few millimeters to many centimeters and usually have convex borders well-demarcated from the surrounding normal skin.</p><p>Vitiligo may show more than one color shade. Trichrome lesions are characterized by zones of white, light-brown, and normal skin color and are most often observed in individuals with darkly pigmented skin. Quadrichrome lesions may have a perifollicular or marginal hyperpigmentation, whereas pentachrome lesions present also a blue hue [<a href="#rid12">12,72</a>]. Another clinical variant is the so-called vitiligo ponctué, which exhibits tiny, confetti-like depigmented macules.</p><p class="headingAnchor" id="H1629897019"><span class="h2">Koebner phenomenon</span><span class="headingEndMark"> — </span>Repeated mechanical trauma (friction) and other types of physical trauma (eg, scratching, chronic pressure, or cuts) along with allergic or irritant contact reactions may trigger vitiligo on areas such as the neck, elbows, and ankles [<a href="#rid73">73</a>]. This is known as the Koebner phenomenon, also called "isomorphic response," which describes the development of skin disease in sites of skin trauma. The Koebner phenomenon has been reported in 20 to 60 percent of patients with vitiligo [<a href="#rid73">73</a>].</p><p class="headingAnchor" id="H1280294694"><span class="h2">Associated findings</span><span class="headingEndMark"> — </span>Depigmented hairs are often present in lesional skin. While such hairs indicate a reduction or loss of the follicular reservoir for repigmentation, their presence does not invariably preclude the repigmentation of a lesion  (<a class="graphic graphic_picture graphicRef106464" href="/d/graphic/106464.html" rel="external">picture 2</a>). Poliosis, a decrease or absence of melanin or color in head hair, eyebrows, and/or eyelashes, may also be a manifestation of vitiligo  (<a class="graphic graphic_picture graphicRef53173" href="/d/graphic/53173.html" rel="external">picture 3</a>) [<a href="#rid65">65</a>]. Premature graying of scalp hair may occur in patients with vitiligo and in their families.</p><p>Halo nevi, characterized by a surrounding area of depigmentation  (<a class="graphic graphic_picture graphicRef57744" href="/d/graphic/57744.html" rel="external">picture 4A</a>), have been identified in 6 to 26 percent of children with nonsegmental vitiligo and may portend the development of generalized vitiligo [<a href="#rid74">74-77</a>]. (See  <a class="medical medical_review" href="/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)", section on 'Halo nevi'</a>.)</p><p>Based upon the analysis of a large series of patients with vitiligo, two age-related clinical phenotypes have been identified [<a href="#rid78">78</a>]. Patients with childhood onset (before age 12 years) often have a family history of vitiligo and/or premature hair graying, associated halo nevi, and Koebner phenomenon, and report previous episodes of depigmentation and repigmentation. In contrast, patients with vitiligo onset during adolescence or early adulthood frequently report a personal or family history of autoimmune diseases and have disease localized to the face and/or acral sites [<a href="#rid78">78</a>].</p><p class="headingAnchor" id="H1414966922"><span class="h2">Clinical classification</span><span class="headingEndMark"> — </span>A detailed classification scheme for vitiligo was proposed in 2012 by the Vitiligo Global Issues Consensus Conference [<a href="#rid11">11</a>]. Vitiligo is classified in two broad categories: nonsegmental vitiligo (the most common) and segmental vitiligo  (<a class="graphic graphic_table graphicRef107278" href="/d/graphic/107278.html" rel="external">table 1</a>). Nonsegmental vitiligo is further divided into subtypes based upon the distribution of skin lesions (ie, generalized, acral or acrofacial, mucosal, localized, universal, and mixed pattern). Rare subtypes are included in the undetermined/unclassified group.</p><p class="headingAnchor" id="H2298024309"><span class="h3">Nonsegmental vitiligo</span><span class="headingEndMark"> — </span>Nonsegmental vitiligo includes the generalized, acrofacial or acral, mucosal, and universal subtypes  (<a class="graphic graphic_table graphicRef107278" href="/d/graphic/107278.html" rel="external">table 1</a>). Generalized and acral or acrofacial vitiligo are most common:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Generalized vitiligo</strong> – Generalized vitiligo is characterized by bilateral, often symmetrical, depigmented macules or patches occurring in a random distribution over multiple areas of the body surface. Generalized vitiligo may begin in childhood or early adulthood and often occurs at sites subjected to pressure, friction, and/or trauma. Depigmented patches are common on the face, trunk, and extremities.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Acrofacial or acral vitiligo</strong> – Acrofacial or acral vitiligo consists of depigmented macules confined to the distal extremities and/or the face  (<a class="graphic graphic_picture graphicRef105860" href="/d/graphic/105860.html" rel="external">picture 5</a>). It may later include other body sites, resulting in typical generalized vitiligo [<a href="#rid2">2,11</a>]. A subcategory of the acrofacial type is the lip-tip variety, in which lesions are confined to the cutaneous lips  (<a class="graphic graphic_picture graphicRef51865" href="/d/graphic/51865.html" rel="external">picture 6</a>) and distal tips of the digits.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mucosal vitiligo</strong> – Mucosal vitiligo typically involves the oral and/or genital mucosa. It may occur in the context of generalized vitiligo or as an isolated manifestation [<a href="#rid79">79</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Universal vitiligo</strong> – Universal vitiligo refers to complete or nearly complete depigmentation of the skin. Some skin areas and hairs may be partially spared. Universal vitiligo usually results from progression of generalized vitiligo.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vitiligo minor</strong> – Vitiligo minor or hypochromic vitiligo is characterized by an incomplete loss of pigmentation resulting in areas of the skin that are paler than the surrounding skin. Vitiligo minor is more frequently seen in individuals with darkly pigmented skin [<a href="#rid80">80</a>].</p><p></p><p class="headingAnchor" id="H1807895961"><span class="h3">Segmental vitiligo</span><span class="headingEndMark"> — </span>Segmental vitiligo typically occurs in a dermatomal or quasi-dermatomal pattern, most frequently along the distribution of the trigeminal nerve  (<a class="graphic graphic_picture graphicRef105859" href="/d/graphic/105859.html" rel="external">picture 7</a>). While being the least common type of vitiligo, segmental vitiligo begins during childhood or early adulthood in most cases [<a href="#rid8">8,81</a>]. In a series of 925 patients with segmental vitiligo from a Chinese Han population, 59 percent developed segmental vitiligo before age 20, and 80 percent developed segmental vitiligo before age 30 [<a href="#rid82">82</a>]. The areas of depigmentation usually stabilize within a year and rarely spread beyond the affected dermatome. There is early involvement of hair follicles (leukotrichia), with histologic evidence of destruction of the follicular melanocyte reservoir.</p><p>Plurisegmental vitiligo may have multiple segments involved, either unilaterally or bilaterally. The onset of different segmental lesions may or may not be simultaneous. Plurisegmental vitiligo can be differentiated from bilateral nonsegmental vitiligo by the restriction of the lesions to identifiable segments, presence of leukotrichia, and protracted course.</p><p class="headingAnchor" id="H2572679193"><span class="h2">Ocular involvement</span><span class="headingEndMark"> — </span>Melanocytes of the eye, ear, and leptomeninges also may be affected in vitiligo [<a href="#rid83">83,84</a>]. Depigmented areas of the retinal pigment epithelium and choroid have been reported in 30 to 40 percent of patients [<a href="#rid85">85-87</a>]. These asymptomatic lesions do not interfere with visual acuity.</p><p class="headingAnchor" id="H3689237287"><span class="h1">ASSOCIATED DISORDERS</span></p><p class="headingAnchor" id="H1049728264"><span class="h2">Autoimmune diseases</span><span class="headingEndMark"> — </span>Vitiligo is frequently associated with autoimmune thyroid disease and other autoimmune or immune-mediated diseases, including alopecia areata, psoriasis, type 1 diabetes, rheumatoid arthritis, inflammatory bowel disease, pernicious anemia, linear morphea, myasthenia gravis, discoid and systemic lupus erythematosus, and Sjögren's disease [<a href="#rid13">13,88-94</a>]. Patients with comorbid autoimmune diseases are more likely to have generalized vitiligo compared with patients without associated diseases [<a href="#rid91">91</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>In a review of 2441 adult patients (mean age 51 years) with vitiligo, 12 percent had an autoimmune thyroid disorder, 8 percent psoriasis, 3 percent rheumatoid arthritis, and 2 percent inflammatory bowel disease [<a href="#rid89">89</a>]. Approximately 40 percent of patients had elevated antinuclear antibodies and 50 percent elevated antibodies to thyroid peroxidase.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another retrospective study of 1098 patients with vitiligo, approximately 20 percent had one or more comorbid autoimmune diseases, most commonly thyroid disease (12 percent) [<a href="#rid91">91</a>]. Alopecia areata was the second most common comorbid disease (2.8 percent), followed by psoriasis, inflammatory bowel disease, and type 1 diabetes mellitus.</p><p></p><p>Vitiligo may also be a clinical feature of polyglandular autoimmune syndromes, in particular autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED; polyglandular autoimmune syndrome type 1 [PAS1]) and Addison's disease with autoimmune thyroid disease (Schmidt's syndrome) [<a href="#rid95">95,96</a>].</p><p class="headingAnchor" id="H2618856702"><span class="h2">Genetic syndromes</span><span class="headingEndMark"> — </span>Vitiligo is associated with several genetic disorders, which include:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Vogt-Koyanagi-Harada syndrome</strong> – Vogt-Koyanagi-Harada syndrome is a rare multisystem disease characterized by chronic uveitis, poliosis (decrease or absence of melanin or color in head hair), alopecia, dysacousia, vitiligo, and signs of meningeal irritation [<a href="#rid97">97</a>]. Vogt-Koyanagi-Harada syndrome usually manifests in the third decade of life and, although reported in all ethnic groups, tends to be more severe in populations with darkly pigmented skin. (See  <a class="medical medical_review" href="/d/html/5581.html" rel="external">"Uveitis: Etiology, clinical manifestations, and diagnosis", section on 'Systemic inflammatory diseases'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Alezzandrini syndrome</strong> – Alezzandrini syndrome is a rare condition characterized by unilateral facial vitiligo, unilateral retinal degeneration, poliosis (decrease or absence of melanin or color in head hair), and hearing loss [<a href="#rid98">98,99</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Kabuki syndrome</strong> – Kabuki syndrome is a rare multisystem disorder caused by mutations in the <em>KMT2D</em> and <em>KDMA6 </em>genes and characterized by developmental delay, mild to moderate intellectual disability, skeletal and visceral anomalies, dermatoglyphic anomalies, and a characteristic facial dysmorphism [<a href="#rid100">100</a>]. Some of these patients also have immunologic defects and/or autoimmune diseases, including vitiligo [<a href="#rid101">101-103</a>].</p><p></p><p class="headingAnchor" id="H3413873813"><span class="h2">Melanoma</span><span class="headingEndMark"> — </span>Rarely, hypopigmented patches resembling vitiligo may precede a diagnosis of cutaneous melanoma [<a href="#rid104">104-106</a>]. The presence of vitiligo-like depigmentation in patients with melanoma is thought to be a marker of an immune response against the tumor and may be an indicator of favorable prognosis in advanced disease [<a href="#rid47">47,107</a>].</p><p class="headingAnchor" id="H1259403518"><span class="h2">Psychosocial issues</span><span class="headingEndMark"> — </span>Vitiligo may be a psychologically devastating disorder, with a major impact on the patient's self-image and self-esteem [<a href="#rid9">9,108</a>]. The mental health and emotional burden of vitiligo is more severe in female patients and in individuals with darkly pigmented skin, in whom the lesions of vitiligo are more prominent [<a href="#rid2">2,109-111</a>]. A 2018 systematic review and meta-analysis of 25 studies including over 2000 patients with vitiligo found a pooled prevalence of depression of 29 percent (95% CI 21-38 percent), based on depression-speciﬁc questionnaires [<a href="#rid112">112</a>].</p><p>In some countries, the confusion with leprosy is an important cause of social stigma and isolation. Children with vitiligo may suffer from severe psychologic trauma, resulting in impaired social and emotional development and compromised quality of life later in adulthood [<a href="#rid113">113,114</a>].</p><p class="headingAnchor" id="H3058952904"><span class="h1">CLINICAL COURSE</span><span class="headingEndMark"> — </span>The clinical course of vitiligo is unpredictable. Lesions can remain stable or progress slowly for years [<a href="#rid2">2</a>]. In most cases, the extent and distribution of lesions change during the course of a person's lifetime by centrifugal expansion of current lesions and/or the appearance of new lesions. Progression is more common in patients who have a family history of nonsegmental vitiligo, a longer duration of disease, Koebner phenomenon, and mucosal involvement, but the rate of progression in the individual patient is unpredictable [<a href="#rid2">2,12,14</a>].</p><p>Flare-ups are common and may be separated by stable periods. Stable vitiligo is most common in children and adolescents, regardless of ethnicity and skin type [<a href="#rid81">81</a>]. Lesions can be considered stable if no change is detected by serial photography in a 12-month period [<a href="#rid11">11</a>].</p><p class="headingAnchor" id="H1295712032"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H1658182713"><span class="h2">Clinical</span><span class="headingEndMark"> — </span>The diagnosis of vitiligo is in most cases straightforward, based upon the clinical finding of acquired, discrete, well-demarcated, uniformly white macules with convex borders surrounded by normal skin in the absence of inflammation or textural changes [<a href="#rid12">12,14,115</a>]. Elements of history that are helpful for the diagnosis include:</p><p class="bulletIndent1"><span class="glyph">●</span>Age at onset of lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Factors or events that may have preceded onset</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms associated with the lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Progression or spread of lesions</p><p class="bulletIndent1"><span class="glyph">●</span>Changes observed in lesions over time</p><p class="bulletIndent1"><span class="glyph">●</span>Presence of concomitant diseases</p><p class="bulletIndent1"><span class="glyph">●</span>Current medications</p><p class="bulletIndent1"><span class="glyph">●</span>Occupational history/exposure to chemicals</p><p class="bulletIndent1"><span class="glyph">●</span>Family history of vitiligo and autoimmune diseases</p><p></p><p class="headingAnchor" id="H3294998736"><span class="h2">Diagnostic aids</span><span class="headingEndMark"> — </span>The diagnosis of vitiligo may be facilitated by the use of a Wood's lamp (a handheld device emitting ultraviolet A light at approximately a 365 nm wavelength), especially in individuals with pale skin [<a href="#rid14">14</a>]. Under the Wood's light, the depigmented areas emit a bright blue-white fluorescence and appear sharply demarcated [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/5562.html" rel="external">"Office-based dermatologic diagnostic procedures", section on 'Wood's lamp examination (black light)'</a>.)</p><p>Dermoscopy may be helpful in differentiating evolving vitiligo patches from other diseases with similar patterns of hypopigmentation. On dermoscopy, vitiliginous macules typically show residual perifollicular pigmentation and telangiectasia, which are absent in other hypopigmentation disorders [<a href="#rid116">116,117</a>]. </p><p class="headingAnchor" id="H170451075"><span class="h2">Pathology</span><span class="headingEndMark"> — </span>A skin biopsy is not routinely required for the diagnosis of vitiligo. However, the examination of a skin biopsy that includes the lesion border and an adjacent, uninvolved area of skin, along with careful clinicopathologic correlation, may be helpful to establish the diagnosis in patients with hypopigmented or depigmented lesions of questionable etiology. On histology, vitiligo reveals complete loss of melanin pigment in the epidermis and absence of melanocytes, with occasional lymphocytes at the advancing border of the lesions  (<a class="graphic graphic_picture graphicRef106596" href="/d/graphic/106596.html" rel="external">picture 8</a>). Other findings include vacuolar degeneration of basal and parabasal keratinocytes, focal spongiosis, and a dermal lymphohistiocytic infiltrate at the dermoepidermal interface, especially in perilesional skin of actively spreading vitiligo [<a href="#rid118">118,119</a>]. Immunohistochemical staining shows a preponderance of CD8<sup>+</sup> T lymphocytes in the inflammatory infiltrate [<a href="#rid120">120</a>].</p><p class="headingAnchor" id="H960685699"><span class="h2">Laboratory studies</span><span class="headingEndMark"> — </span>Given the relatively high frequency of the association of vitiligo with autoimmune thyroid disease, it is reasonable to screen all patients with vitiligo, and especially those with generalized disease and extensive involvement of the body surface, for thyroid function [<a href="#rid90">90,121,122</a>]. (See <a class="local">'Associated disorders'</a> above.)</p><p>European guidelines based upon expert consensus recommend the assessment of thyroid function (thyroid-stimulating hormone, antithyroperoxidase, and antithyroglobulin antibodies) in all patients with vitiligo [<a href="#rid57">57</a>]. They also recommend the measurement of additional autoantibodies only if the patient's history, family history, or physical examination suggests other autoimmune diseases. Low-titer antinuclear antibody positivity may not preclude the use of phototherapy and may not be associated with increased risk of phototoxic reactions [<a href="#rid123">123</a>]. (See  <a class="medical medical_review" href="/d/html/1822.html" rel="external">"Measurement and clinical significance of antinuclear antibodies"</a>.)</p><p class="headingAnchor" id="H1206141537"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>Many common and uncommon disorders are characterized by areas of depigmentation that may mimic vitiligo [<a href="#rid10">10,14,124-129</a>].<sup> </sup>To differentiate vitiligo from mimickers, it is important to evaluate the skin texture and whether there is or is not complete depigmentation. Vitiligo is <strong>not</strong> associated with scaling or textural changes, although some patients may rarely develop inflammatory vitiligo characterized by raised, erythematous borders.</p><p>Conditions that are frequently confused with vitiligo include (see  <a class="medical medical_review" href="/d/html/103736.html" rel="external">"Acquired hypopigmentation disorders other than vitiligo"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Nevus depigmentosus</strong> – Nevus depigmentosus  (<a class="graphic graphic_picture graphicRef106603" href="/d/graphic/106603.html" rel="external">picture 9</a>) is a circumscribed, segmental area of depigmentation or hypopigmentation usually present at birth or detected in the first years of life [<a href="#rid14">14</a>]. The lesion shows little change over time, although it may enlarge as the patient grows. Nevus depigmentosus is a form of cutaneous mosaicism, caused by an altered clone of melanocytes with a decreased ability to produce melanin, abnormal melanosomes, and inability to transfer pigment to keratinocytes [<a href="#rid130">130,131</a>]. When seen under a Wood's lamp, the contrast between lesional and normal skin is less marked than in vitiligo [<a href="#rid12">12,14</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pityriasis alba</strong> – Pityriasis alba commonly affects children and is considered a component of the spectrum of atopic dermatitis. It is characterized by hypopigmented, mildly scaling patches common on sun-exposed areas  (<a class="graphic graphic_picture graphicRef60866 graphicRef73576" href="/d/graphic/60866.html" rel="external">picture 10A-B</a>). Such patches usually clear with or without treatment with low-potency corticosteroids. (See  <a class="medical medical_review" href="/d/html/103736.html" rel="external">"Acquired hypopigmentation disorders other than vitiligo", section on 'Pityriasis alba'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Idiopathic guttate hypomelanosis</strong> – Idiopathic guttate hypomelanosis is a common disorder characterized by multiple small, asymptomatic, porcelain-white macules primarily on the sun-exposed areas of the limbs  (<a class="graphic graphic_picture graphicRef67346 graphicRef61761" href="/d/graphic/67346.html" rel="external">picture 11A-B</a>) [<a href="#rid72">72,132</a>]. Its incidence increases with age and is seen in up to 80 percent of patients over the age of 70 years. Once present, lesions do not change in size or coalesce. Melanocytes are present, although they may be reduced in number. (See  <a class="medical medical_review" href="/d/html/103736.html" rel="external">"Acquired hypopigmentation disorders other than vitiligo", section on 'Idiopathic guttate hypomelanosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Tinea versicolor</strong> – Tinea versicolor (pityriasis versicolor) is a superficial yeast infection that can cause loss of pigment. It is caused by saprophytic, lipid-dependent yeasts in the genus <em>Malassezia</em> (<em>Pityrosporum</em>)<em>. </em>It presents as pale macules typically located on the upper trunk and chest, with a fine, dry surface scale  (<a class="graphic graphic_picture graphicRef100021" href="/d/graphic/100021.html" rel="external">picture 12</a>) [<a href="#rid12">12,50</a>]. Involved areas often fluoresce a golden yellow when examined under a Wood's lamp [<a href="#rid12">12</a>]. (See  <a class="medical medical_review" href="/d/html/4039.html" rel="external">"Tinea versicolor (pityriasis versicolor)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Halo nevus</strong> – Halo nevus, also called Sutton nevus, is a melanocytic nevus surrounded by a round or oval halo of depigmentation  (<a class="graphic graphic_picture graphicRef57744 graphicRef65988" href="/d/graphic/57744.html" rel="external">picture 4A-B</a>) [<a href="#rid133">133</a>]. This pigment loss often heralds the spontaneous regression of the central nevus. A single circular lesion on the trunk of a young person may represent a resolving halo nevus. (See  <a class="medical medical_review" href="/d/html/4846.html" rel="external">"Acquired melanocytic nevi (moles)", section on 'Halo nevi'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Piebaldism</strong> – Piebaldism (MIM #172800) is a rare autosomal-dominant disorder presenting at birth with anterior midline depigmentation and a white forelock (poliosis)  (<a class="graphic graphic_picture graphicRef52591" href="/d/graphic/52591.html" rel="external">picture 13</a>). Irregular depigmented areas may also be present on the trunk and extremities. Rarely, lesions show a hyperpigmented border [<a href="#rid125">125</a>]. Distribution on the forehead and chin supports the diagnosis.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Progressive macular hypomelanosis</strong> – Progressive macular hypomelanosis is characterized by nonscaling hypopigmented patches of the trunk caused by <em>Cutibacterium</em> (formerly <em>Propionibacterium</em>) <em>acnes</em>  (<a class="graphic graphic_picture graphicRef107626" href="/d/graphic/107626.html" rel="external">picture 14</a>). The condition is most common in young patients. (See  <a class="medical medical_review" href="/d/html/103736.html" rel="external">"Acquired hypopigmentation disorders other than vitiligo", section on 'Progressive macular hypomelanosis'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Lichen sclerosus</strong> – Lichen sclerosus is an uncommon condition characterized by atrophic, white, firm lesions that most commonly affect the anogenital area but may also affect extragenital skin. Vitiligo affecting only the genital area can be difficult to differentiate from lichen sclerosus, which can also coexist with vitiligo. A skin biopsy may be necessary to clarify the diagnosis in difficult cases. (See  <a class="medical medical_review" href="/d/html/15838.html" rel="external">"Extragenital lichen sclerosus: Clinical features and diagnosis"</a> and  <a class="medical medical_review" href="/d/html/5558.html" rel="external">"Vulvar lichen sclerosus: Clinical manifestations and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Chemical leukoderma</strong> – Chemical leukoderma initially presents with depigmentation at the contact area but may later spread to other areas  (<a class="graphic graphic_picture graphicRef107622" href="/d/graphic/107622.html" rel="external">picture 15</a>). Occupational hazards for chemical leukoderma include phenolic-catecholic derivatives including monobenzyl ether of <a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">hydroquinone</a> (monobenzone), para tertiary butyl catechol, para tertiary butyl phenol, paraphenylenediamine and amino phenol, para tertiary amyl phenol, hydroquinone, and monomethyl ether [<a href="#rid14">14</a>].</p><p></p><p class="bulletIndent1">Leukoderma secondary to chemicals can also be induced by dyes, perfumes, detergents, cleansers, insecticides, rubber condoms, rubber slippers, black socks and shoes, eyeliner, lip liner, lipstick, toothpaste, antiseptics with phenolic derivatives, mercuric iodide-containing "germicidal" soap, and arsenic-containing compounds [<a href="#rid134">134,135</a>]. In 2013, thousands of patients in Japan developed depigmentation after using a brightening cream containing rhododendrol (4-[4-hydroxyphenyl]-2butanol), a competitive inhibitor of tyrosinase [<a href="#rid136">136,137</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="8539" href="/d/drug information/8539.html" rel="external">Hydroquinone</a>, a depigmenting agent widely used for the treatment of melasma, induces a reversible hypopigmentation of the skin at the site of application. In contrast, monobenzone, which is used as a depigmenting agent in the treatment of widespread vitiligo, can induce a permanent and generalized depigmentation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Drug-induced leukoderma</strong> – Potent topical or intralesional corticosteroids may induce hypopigmentation at the site of application, particularly in individuals with darkly pigmented skin. Depigmentation mimicking vitiligo may occur in patients treated with the epidermal growth factor receptor inhibitor <a class="drug drug_general" data-topicid="8712" href="/d/drug information/8712.html" rel="external">gefitinib</a>, the tyrosine kinase inhibitor <a class="drug drug_general" data-topicid="8961" href="/d/drug information/8961.html" rel="external">imatinib</a> mesylate [<a href="#rid138">138,139</a>], interferon pegylated [<a href="#rid140">140,141</a>], and transdermal <a class="drug drug_general" data-topicid="9638" href="/d/drug information/9638.html" rel="external">methylphenidate</a> patch [<a href="#rid135">135</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hypopigmented mycosis fungoides</strong> – Hypopigmented mycosis fungoides is an uncommon variant of early-stage mycosis fungoides seen more often in children and in patients with darkly pigmented skin  (<a class="graphic graphic_picture graphicRef106609 graphicRef71926" href="/d/graphic/106609.html" rel="external">picture 16A-B</a>) [<a href="#rid142">142,143</a>]. It presents with widespread hypopigmented patches with mild scaling and atrophy. Telangiectasias may also be present in the lesions. Histopathology does not show a complete absence of melanocytes but rather a minimal number of melanocytes as well as the morphologic and immunophenotypic findings suggestive of cutaneous T cell lymphoma. (See  <a class="medical medical_review" href="/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a>.)</p><p></p><p>Additional conditions that should be differentiated from vitiligo include postinflammatory hypopigmentation, leukoderma associated with melanoma and scleroderma, and the late stages of treponematosis and onchocerciasis.</p><p class="headingAnchor" id="H2709515976"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/122181.html" rel="external">"Society guideline links: Vitiligo"</a>.)</p><p class="headingAnchor" id="H2227404688"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/90326.html" rel="external">"Patient education: Vitiligo (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H3122791531"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology and pathogenesis</strong> – Vitiligo is an acquired disorder of pigmentation, affecting approximately 1 percent of the world population. The pathogenesis of vitiligo is likely multifactorial and may involve genetic, autoimmune, neural, and biochemical factors and oxidative stress. (See <a class="local">'Epidemiology'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical presentation</strong> – Vitiligo typically presents with asymptomatic, depigmented macules and patches that lack clinical signs of inflammation  (<a class="graphic graphic_picture graphicRef106463" href="/d/graphic/106463.html" rel="external">picture 1</a>). Lesions can appear at any age and anywhere on the body. Based upon the distribution pattern of depigmented lesions, vitiligo is classified into two broad categories, segmental  (<a class="graphic graphic_picture graphicRef105859" href="/d/graphic/105859.html" rel="external">picture 7</a>) and nonsegmental (most common), and in several subtypes, such as generalized, acral or acrofacial, and universal  (<a class="graphic graphic_table graphicRef107278" href="/d/graphic/107278.html" rel="external">table 1</a>). (See <a class="local">'General features'</a> above and <a class="local">'Clinical classification'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated disorders</strong> – Vitiligo is frequently associated with autoimmune thyroid disease. Alopecia areata, psoriasis, inflammatory bowel disease, and several other autoimmune and genetic disorders have also been linked to vitiligo. (See <a class="local">'Associated disorders'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of vitiligo is made clinically in most cases. A skin biopsy can be performed in patients with hypopigmented or depigmented lesions of uncertain etiology. Given the relatively high frequency with which autoimmune thyroid disease occurs in patients with vitiligo, it is reasonable to screen all patients with vitiligo for thyroid function. (See <a class="local">'Diagnosis'</a> above and <a class="local">'Laboratory studies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Zedan H, Abdel-Motaleb AA, Kassem NM, et al. Low glutathione peroxidase activity levels in patients with vitiligo. J Cutan Med Surg 2015; 19:144.</a></li><li><a class="nounderline abstract_t">Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet 2015; 386:74.</a></li><li><a class="nounderline abstract_t">Mohammed GF, Gomaa AH, Al-Dhubaibi MS. Highlights in pathogenesis of vitiligo. World J Clin Cases 2015; 3:221.</a></li><li class="breakAll">Ortonne J-P, Passeron T. Vitiligo and other disorders of hypopigmentation. In: Dermatology, 3rd ed, Boloniga JL, Jorizzo JL, Schaffer JV (Eds), Elsevier, 2012. p.1023.</li><li><a class="nounderline abstract_t">Krüger C, Schallreuter KU. Stigmatisation, Avoidance Behaviour and Difficulties in Coping are Common Among Adult Patients with Vitiligo. Acta Derm Venereol 2015; 95:553.</a></li><li><a class="nounderline abstract_t">Silverberg JI, Silverberg NB. Quality of life impairment in children and adolescents with vitiligo. Pediatr Dermatol 2014; 31:309.</a></li><li class="breakAll">Robins A. Biological Perspectives on Human Pigmentation, Cambridge University Press, 2005. Vol 7.</li><li class="breakAll">Grimes PE. Disorders of pigmentation. In: ACP Medicine, Dale DC, Federman DD (Eds), WebMD Scientific American Medicine, 2012. p.526.</li><li class="breakAll">Porter J. The psychological effects of vitiligo: Response to impaired appearance. In: Vitiligo, Hann SK, Nordlund JJ (Eds), Blackwell Science, 2000. p.97.</li><li><a class="nounderline abstract_t">Daniel BS, Wittal R. Vitiligo treatment update. Australas J Dermatol 2015; 56:85.</a></li><li><a class="nounderline abstract_t">Ezzedine K, Lim HW, Suzuki T, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigment Cell Melanoma Res 2012; 25:E1.</a></li><li><a class="nounderline abstract_t">Yaghoobi R, Omidian M, Bagherani N. Vitiligo: a review of the published work. J Dermatol 2011; 38:419.</a></li><li><a class="nounderline abstract_t">Alkhateeb A, Fain PR, Thody A, et al. Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families. Pigment Cell Res 2003; 16:208.</a></li><li><a class="nounderline abstract_t">Alikhan A, Felsten LM, Daly M, Petronic-Rosic V. Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol 2011; 65:473.</a></li><li><a class="nounderline abstract_t">Krüger C, Schallreuter KU. A review of the worldwide prevalence of vitiligo in children/adolescents and adults. Int J Dermatol 2012; 51:1206.</a></li><li><a class="nounderline abstract_t">Lee H, Lee MH, Lee DY, et al. Prevalence of vitiligo and associated comorbidities in Korea. Yonsei Med J 2015; 56:719.</a></li><li><a class="nounderline abstract_t">Bibeau K, Pandya AG, Ezzedine K, et al. Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA. J Eur Acad Dermatol Venereol 2022; 36:1831.</a></li><li><a class="nounderline abstract_t">Gandhi K, Ezzedine K, Anastassopoulos KP, et al. Prevalence of Vitiligo Among Adults in the United States. JAMA Dermatol 2022; 158:43.</a></li><li><a class="nounderline abstract_t">Mastacouris N, Strunk A, Garg A. Incidence and Prevalence of Diagnosed Vitiligo According to Race and Ethnicity, Age, and Sex in the US. JAMA Dermatol 2023; 159:986.</a></li><li><a class="nounderline abstract_t">Conrad N, Misra S, Verbakel JY, et al. Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK. Lancet 2023; 401:1878.</a></li><li class="breakAll">Grimes PE, Billips M. Childhood vitiligo: Clinical spectrum and therapeutic approaches. In: Vitiligo, Hann SK, Nordlund JJ (Eds), Blackwell Science, 2000. p.61.</li><li><a class="nounderline abstract_t">Khalil A, Zaidman I, Bergman R, et al. Autoimmune complications after hematopoietic stem cell transplantation in children with nonmalignant disorders. ScientificWorldJournal 2014; 2014:581657.</a></li><li><a class="nounderline abstract_t">Sanli H, Akay BN, Arat M, et al. Vitiligo after hematopoietic cell transplantation: six cases and review of the literature. Dermatology 2008; 216:349.</a></li><li><a class="nounderline abstract_t">Bae JM, Choi KH, Jung HM, et al. Subsequent vitiligo after hematopoietic stem cell transplantation: A nationwide population-based cohort study from Korea. J Am Acad Dermatol 2017; 76:459.</a></li><li><a class="nounderline abstract_t">Neumeister P, Strunk D, Apfelbeck U, et al. Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma. Lancet 2000; 355:1334.</a></li><li><a class="nounderline abstract_t">Zuo RC, Naik HB, Steinberg SM, et al. Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease. JAMA Dermatol 2015; 151:23.</a></li><li><a class="nounderline abstract_t">Grimes PE. New insights and new therapies in vitiligo. JAMA 2005; 293:730.</a></li><li><a class="nounderline abstract_t">Njoo MD, Westerhof W. Vitiligo. Pathogenesis and treatment. Am J Clin Dermatol 2001; 2:167.</a></li><li><a class="nounderline abstract_t">Le Poole IC, Das PK, van den Wijngaard RM, et al. Review of the etiopathomechanism of vitiligo: a convergence theory. Exp Dermatol 1993; 2:145.</a></li><li><a class="nounderline abstract_t">Bhatia PS, Mohan L, Pandey ON, et al. Genetic nature of vitiligo. J Dermatol Sci 1992; 4:180.</a></li><li><a class="nounderline abstract_t">Majumder PP, Das SK, Li CC. A genetical model for vitiligo. Am J Hum Genet 1988; 43:119.</a></li><li><a class="nounderline abstract_t">Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity cross-validated. Am J Hum Genet 1994; 55:981.</a></li><li><a class="nounderline abstract_t">Fain PR, Gowan K, LaBerge GS, et al. A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. Am J Hum Genet 2003; 72:1560.</a></li><li><a class="nounderline abstract_t">Czajkowski R, Męcińska-Jundziłł K. Current aspects of vitiligo genetics. Postepy Dermatol Alergol 2014; 31:247.</a></li><li><a class="nounderline abstract_t">Thorsby E, Lie BA. HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms. Transpl Immunol 2005; 14:175.</a></li><li><a class="nounderline abstract_t">Orecchia G, Perfetti L, Malagoli P, et al. Vitiligo is associated with a significant increase in HLA-A30, Cw6 and DQw3 and a decrease in C4AQ0 in northern Italian patients. Dermatology 1992; 185:123.</a></li><li><a class="nounderline abstract_t">Jin Y, Birlea SA, Fain PR, et al. Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo. N Engl J Med 2010; 362:1686.</a></li><li><a class="nounderline abstract_t">Quan C, Ren YQ, Xiang LH, et al. Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC. Nat Genet 2010; 42:614.</a></li><li><a class="nounderline abstract_t">Jin Y, Birlea SA, Fain PR, et al. Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo. Nat Genet 2012; 44:676.</a></li><li><a class="nounderline abstract_t">Tang XF, Zhang Z, Hu DY, et al. Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population. J Invest Dermatol 2013; 133:403.</a></li><li><a class="nounderline abstract_t">Alkhateeb A, Fain PR, Spritz RA. Candidate functional promoter variant in the FOXD3 melanoblast developmental regulator gene in autosomal dominant vitiligo. J Invest Dermatol 2005; 125:388.</a></li><li><a class="nounderline abstract_t">Chen JJ, Huang W, Gui JP, et al. A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families. Am J Hum Genet 2005; 76:1057.</a></li><li><a class="nounderline abstract_t">Jin Y, Mailloux CM, Gowan K, et al. NALP1 in vitiligo-associated multiple autoimmune disease. N Engl J Med 2007; 356:1216.</a></li><li><a class="nounderline abstract_t">Kovacs SO. Vitiligo. J Am Acad Dermatol 1998; 38:647.</a></li><li><a class="nounderline abstract_t">Boissy RE, Nordlund JJ. Molecular basis of congenital hypopigmentary disorders in humans: a review. Pigment Cell Res 1997; 10:12.</a></li><li><a class="nounderline abstract_t">Betterle C, Caretto A, De Zio A, et al. Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo. Dermatologica 1985; 171:419.</a></li><li><a class="nounderline abstract_t">Grimes PE, Halder RM, Jones C, et al. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983; 119:300.</a></li><li><a class="nounderline abstract_t">Naughton GK, Eisinger M, Bystryn JC. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation. J Invest Dermatol 1983; 81:540.</a></li><li><a class="nounderline abstract_t">Norris DA, Kissinger RM, Naughton GM, Bystryn JC. Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity. J Invest Dermatol 1988; 90:783.</a></li><li><a class="nounderline abstract_t">Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003; 16:90.</a></li><li><a class="nounderline abstract_t">Gilhar A, Pillar T, Eidelman S, Etzioni A. Vitiligo and idiopathic guttate hypomelanosis. Repigmentation of skin following engraftment onto nude mice. Arch Dermatol 1989; 125:1363.</a></li><li><a class="nounderline abstract_t">Ghoneum M, Grimes PE, Gill G, Kelly AP. Natural cell-mediated cytotoxicity in vitiligo. J Am Acad Dermatol 1987; 17:600.</a></li><li><a class="nounderline abstract_t">Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998; 188:1203.</a></li><li><a class="nounderline abstract_t">Richmond JM, Frisoli ML, Harris JE. Innate immune mechanisms in vitiligo: danger from within. Curr Opin Immunol 2013; 25:676.</a></li><li><a class="nounderline abstract_t">van den Boorn JG, Konijnenberg D, Dellemijn TA, et al. Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients. J Invest Dermatol 2009; 129:2220.</a></li><li><a class="nounderline abstract_t">Mandelcorn-Monson RL, Shear NH, Yau E, et al. Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients. J Invest Dermatol 2003; 121:550.</a></li><li><a class="nounderline abstract_t">Taieb A, Alomar A, Böhm M, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol 2013; 168:5.</a></li><li><a class="nounderline abstract_t">Dell'anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigment Cell Res 2006; 19:406.</a></li><li><a class="nounderline abstract_t">Dell'Anna ML, Maresca V, Briganti S, et al. Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo. J Invest Dermatol 2001; 117:908.</a></li><li><a class="nounderline abstract_t">Picardo M, Grammatico P, Roccella F, et al. Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma. J Invest Dermatol 1996; 107:322.</a></li><li><a class="nounderline abstract_t">Morrone A, Picardo M, de Luca C, et al. Catecholamines and vitiligo. Pigment Cell Res 1992; 5:65.</a></li><li><a class="nounderline abstract_t">Hasse S, Gibbons NC, Rokos H, et al. Perturbed 6-tetrahydrobiopterin recycling via decreased dihydropteridine reductase in vitiligo: more evidence for H2O2 stress. J Invest Dermatol 2004; 122:307.</a></li><li><a class="nounderline abstract_t">Schallreuter KU, Wood JM, Lemke KR, Levenig C. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995; 190:223.</a></li><li><a class="nounderline abstract_t">Nordlund JJ. The significance of depigmentation. Pigment Cell Res 1992; Suppl 2:237.</a></li><li><a class="nounderline abstract_t">Nelhaus G. Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery. Neurology 1970; 20:965.</a></li><li><a class="nounderline abstract_t">Al'Abadie MS, Warren MA, Bleehen SS, Gawkrodger DJ. Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study. Int J Dermatol 1995; 34:837.</a></li><li><a class="nounderline abstract_t">Al'Abadie MS, Senior HJ, Bleehen SS, Gawkrodger DJ. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994; 131:160.</a></li><li><a class="nounderline abstract_t">Mozzanica N, Villa ML, Foppa S, et al. Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 1992; 26:693.</a></li><li><a class="nounderline abstract_t">Tu C, Zhao D, Lin X. Levels of neuropeptide-Y in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 2001; 27:178.</a></li><li><a class="nounderline abstract_t">Gauthier Y, Cario-Andre M, Lepreux S, et al. Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo. Br J Dermatol 2003; 148:95.</a></li><li><a class="nounderline abstract_t">Vrijman C, Hosseinpour D, Bakker JG, et al. Provoking factors, including chemicals, in Dutch patients with vitiligo. Br J Dermatol 2013; 168:1003.</a></li><li><a class="nounderline abstract_t">Taïeb A, Picardo M, VETF Members. The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force. Pigment Cell Res 2007; 20:27.</a></li><li><a class="nounderline abstract_t">van Geel N, Speeckaert R, Taieb A, et al. Koebner's phenomenon in vitiligo: European position paper. Pigment Cell Melanoma Res 2011; 24:564.</a></li><li><a class="nounderline abstract_t">Cohen BE, Mu EW, Orlow SJ. Comparison of Childhood Vitiligo Presenting with or without Associated Halo Nevi. Pediatr Dermatol 2016; 33:44.</a></li><li><a class="nounderline abstract_t">Marinho Fde S, Cirino PV, Fernandes NC. Clinical epidemiological profile of vitiligo in children and adolescents. An Bras Dermatol 2013; 88:1026.</a></li><li><a class="nounderline abstract_t">Ezzedine K, Diallo A, Léauté-Labrèze C, et al. Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients. Br J Dermatol 2011; 165:44.</a></li><li><a class="nounderline abstract_t">Silverberg NB. Pediatric vitiligo. Pediatr Clin North Am 2014; 61:347.</a></li><li><a class="nounderline abstract_t">Ezzedine K, Le Thuaut A, Jouary T, et al. Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes. Pigment Cell Melanoma Res 2014; 27:134.</a></li><li><a class="nounderline abstract_t">Nagarajan A, Masthan MK, Sankar LS, et al. Oral manifestations of vitiligo. Indian J Dermatol 2015; 60:103.</a></li><li><a class="nounderline abstract_t">Ezzedine K, Mahé A, van Geel N, et al. Hypochromic vitiligo: delineation of a new entity. Br J Dermatol 2015; 172:716.</a></li><li><a class="nounderline abstract_t">de Barros JC, Machado Filho CD, Abreu LC, et al. A study of clinical profiles of vitiligo in different ages: an analysis of 669 outpatients. Int J Dermatol 2014; 53:842.</a></li><li><a class="nounderline abstract_t">Ma J, Cheng L, Wu YY, et al. A retrospective analysis of 925 cases of segmental vitiligo in a Chinese Han population. J Eur Acad Dermatol Venereol 2021; 35:e379.</a></li><li><a class="nounderline abstract_t">Ciardella AP, Horsley MB, Brown DM. Hypopigmentary fundus changes seen with cutaneous vitiligo. Arch Ophthalmol 2007; 125:576.</a></li><li><a class="nounderline abstract_t">Vingerling JR, Owens S, van der Meijden WI, et al. Cutaneous vitiligo associated with choroidal hypopigmentation. Eye (Lond) 2004; 18:939.</a></li><li><a class="nounderline abstract_t">Albert DM, Wagoner MD, Pruett RC, et al. Vitiligo and disorders of the retinal pigment epithelium. Br J Ophthalmol 1983; 67:153.</a></li><li><a class="nounderline abstract_t">Cowan CL Jr, Halder RM, Grimes PE, et al. Ocular disturbances in vitiligo. J Am Acad Dermatol 1986; 15:17.</a></li><li><a class="nounderline abstract_t">Albert DM, Nordlund JJ, Lerner AB. Ocular abnormalities occurring with vitiligo. Ophthalmology 1979; 86:1145.</a></li><li><a class="nounderline abstract_t">Gey A, Diallo A, Seneschal J, et al. Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms. Br J Dermatol 2013; 168:756.</a></li><li><a class="nounderline abstract_t">Sheth VM, Guo Y, Qureshi AA. Comorbidities associated with vitiligo: a ten-year retrospective study. Dermatology 2013; 227:311.</a></li><li><a class="nounderline abstract_t">Vrijman C, Kroon MW, Limpens J, et al. The prevalence of thyroid disease in patients with vitiligo: a systematic review. Br J Dermatol 2012; 167:1224.</a></li><li><a class="nounderline abstract_t">Gill L, Zarbo A, Isedeh P, et al. Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study. J Am Acad Dermatol 2016; 74:295.</a></li><li><a class="nounderline abstract_t">Chen YT, Chen YJ, Hwang CY, et al. Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan. J Eur Acad Dermatol Venereol 2015; 29:1362.</a></li><li><a class="nounderline abstract_t">Chang HC, Lin MH, Huang YC, Hou TY. The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis. J Am Acad Dermatol 2019; 81:1442.</a></li><li><a class="nounderline abstract_t">Rios-Duarte JA, Sanchez-Zapata MJ, Silverberg JI. Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study. Arch Dermatol Res 2023; 315:2597.</a></li><li><a class="nounderline abstract_t">Collins SM, Dominguez M, Ilmarinen T, et al. Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. Br J Dermatol 2006; 154:1088.</a></li><li><a class="nounderline abstract_t">Millar S, Carson D. Clinical phenotypes of autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy seen in the Northern Ireland paediatric population over the last 30 years. Ulster Med J 2012; 81:118.</a></li><li><a class="nounderline abstract_t">Joye A, Suhler E. Vogt-Koyanagi-Harada disease. Curr Opin Ophthalmol 2021; 32:574.</a></li><li><a class="nounderline abstract_t">Andrade A, Pithon M. Alezzandrini syndrome: report of a sixth clinical case. Dermatology 2011; 222:8.</a></li><li><a class="nounderline abstract_t">ALEZZANDRINI AA. [UNILATERAL MANIFESTATIONS OF TAPETO-RETINAL DEGENERATION, VITILIGO, POLIOSIS, GREY HAIR AND HYPOACOUSIA]. Ophthalmologica 1964; 147:409.</a></li><li><a class="nounderline abstract_t">Niikawa N, Matsuura N, Fukushima Y, et al. Kabuki make-up syndrome: a syndrome of mental retardation, unusual facies, large and protruding ears, and postnatal growth deficiency. J Pediatr 1981; 99:565.</a></li><li><a class="nounderline abstract_t">Ming JE, Russell KL, McDonald-McGinn DM, Zackai EH. Autoimmune disorders in Kabuki syndrome. Am J Med Genet A 2005; 132A:260.</a></li><li><a class="nounderline abstract_t">Stagi S, Gulino AV, Lapi E, Rigante D. Epigenetic control of the immune system: a lesson from Kabuki syndrome. Immunol Res 2016; 64:345.</a></li><li><a class="nounderline abstract_t">Zannolli R, Buoni S, Macucci F, et al. Kabuki syndrome with trichrome vitiligo, ectodermal defect and hypogammaglobulinemia A and G. Brain Dev 2007; 29:373.</a></li><li><a class="nounderline abstract_t">Cho EA, Lee MA, Kang H, et al. Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin. Ann Dermatol 2009; 21:178.</a></li><li><a class="nounderline abstract_t">Onsun N, Büyükbabani N, Ummetoğlu O, Cebeci F. Do we have to pay more attention to vitiligo patients? Peculiar histopathological features of primary cutaneous melanoma preceded by vitiligo. J Dermatol 2009; 36:612.</a></li><li><a class="nounderline abstract_t">Redondo P, Del Olmo J. Images in clinical medicine. Vitiligo and cutaneous melanoma. N Engl J Med 2008; 359:e3.</a></li><li><a class="nounderline abstract_t">Quaglino P, Marenco F, Osella-Abate S, et al. Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study. Ann Oncol 2010; 21:409.</a></li><li><a class="nounderline abstract_t">Talsania N, Lamb B, Bewley A. Vitiligo is more than skin deep: a survey of members of the Vitiligo Society. Clin Exp Dermatol 2010; 35:736.</a></li><li><a class="nounderline abstract_t">Pahwa P, Mehta M, Khaitan BK, et al. The psychosocial impact of vitiligo in Indian patients. Indian J Dermatol Venereol Leprol 2013; 79:679.</a></li><li><a class="nounderline abstract_t">Thompson AR, Clarke SA, Newell RJ, et al. Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo. Br J Dermatol 2010; 163:481.</a></li><li><a class="nounderline abstract_t">Linthorst Homan MW, Spuls PI, de Korte J, et al. The burden of vitiligo: patient characteristics associated with quality of life. J Am Acad Dermatol 2009; 61:411.</a></li><li><a class="nounderline abstract_t">Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis. Br J Dermatol 2018; 178:863.</a></li><li><a class="nounderline abstract_t">Lin X, Tang LY, Fu WW, Kang KF. Childhood vitiligo in China: clinical profiles and immunological findings in 620 cases. Am J Clin Dermatol 2011; 12:277.</a></li><li><a class="nounderline abstract_t">Linthorst Homan MW, de Korte J, Grootenhuis MA, et al. Impact of childhood vitiligo on adult life. Br J Dermatol 2008; 159:915.</a></li><li><a class="nounderline abstract_t">Ezzedine K, Silverberg N. A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children. Pediatrics 2016; 138.</a></li><li><a class="nounderline abstract_t">Thatte SS, Khopkar US. The utility of dermoscopy in the diagnosis of evolving lesions of vitiligo. Indian J Dermatol Venereol Leprol 2014; 80:505.</a></li><li><a class="nounderline abstract_t">Meng R, Zhao G, Cai RK, et al. Application of polarized light dermoscopy in the early diagnosis of vitiligo and its differential diagnosis from other depigmented diseases. Chinese J Dermatol 2009; 42:810.</a></li><li><a class="nounderline abstract_t">Montes LF, Abulafia J, Wilborn WH, et al. Value of histopathology in vitiligo. Int J Dermatol 2003; 42:57.</a></li><li><a class="nounderline abstract_t">Yadav AK, Singh P, Khunger N. Clinicopathologic Analysis of Stable and Unstable Vitiligo: A Study of 66 Cases. Am J Dermatopathol 2016; 38:608.</a></li><li><a class="nounderline abstract_t">van Geel NA, Mollet IG, De Schepper S, et al. First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi. Pigment Cell Melanoma Res 2010; 23:375.</a></li><li><a class="nounderline abstract_t">Daneshpazhooh M, Mostofizadeh G M, Behjati J, et al. Anti-thyroid peroxidase antibody and vitiligo: a controlled study. BMC Dermatol 2006; 6:3.</a></li><li><a class="nounderline abstract_t">Kakourou T, Kanaka-Gantenbein C, Papadopoulou A, et al. Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo. J Am Acad Dermatol 2005; 53:220.</a></li><li><a class="nounderline abstract_t">Chaiyabutr C, Wongpraparut C, Charoenpipatsin N, et al. The necessity of antinuclear antibody investigation in pre-phototherapy vitiligo patients: A retrospective study. Photodermatol Photoimmunol Photomed 2020; 36:373.</a></li><li><a class="nounderline abstract_t">Passeron T, Ortonne JP. Physiopathology and genetics of vitiligo. J Autoimmun 2005; 25 Suppl:63.</a></li><li><a class="nounderline abstract_t">Gawkrodger DJ, Ormerod AD, Shaw L, et al. Guideline for the diagnosis and management of vitiligo. Br J Dermatol 2008; 159:1051.</a></li><li><a class="nounderline abstract_t">Bilgiç Ö, Bilgiç A. Possible atomoxetine-induced vitiligo: a case report. Atten Defic Hyperact Disord 2015; 7:179.</a></li><li><a class="nounderline abstract_t">Doğan Z, Özdemir P, Ekşioğlu M, Filik L. Relationship between Helicobacter pylori infection and vitiligo: a prospective study. Am J Clin Dermatol 2014; 15:457.</a></li><li><a class="nounderline abstract_t">Craiglow BG, King BA. Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy. JAMA Dermatol 2015; 151:1110.</a></li><li><a class="nounderline abstract_t">Ezzedine K, Amazan E, Séneschal J, et al. Follicular vitiligo: a new form of vitiligo. Pigment Cell Melanoma Res 2012; 25:527.</a></li><li><a class="nounderline abstract_t">Kim SK, Kang HY, Lee ES, Kim YC. Clinical and histopathologic characteristics of nevus depigmentosus. J Am Acad Dermatol 2006; 55:423.</a></li><li><a class="nounderline abstract_t">Lee HS, Chun YS, Hann SK. Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients. J Am Acad Dermatol 1999; 40:21.</a></li><li><a class="nounderline abstract_t">Shin MK, Jeong KH, Oh IH, et al. Clinical features of idiopathic guttate hypomelanosis in 646 subjects and association with other aspects of photoaging. Int J Dermatol 2011; 50:798.</a></li><li><a class="nounderline abstract_t">Weyant GW, Chung CG, Helm KF. Halo nevus: review of the literature and clinicopathologic findings. Int J Dermatol 2015; 54:e433.</a></li><li><a class="nounderline abstract_t">Ghosh S, Mukhopadhyay S. Chemical leucoderma: a clinico-aetiological study of 864 cases in the perspective of a developing country. Br J Dermatol 2009; 160:40.</a></li><li><a class="nounderline abstract_t">Ghasri P, Gattu S, Saedi N, Ganesan AK. Chemical leukoderma after the application of a transdermal methylphenidate patch. J Am Acad Dermatol 2012; 66:e237.</a></li><li><a class="nounderline abstract_t">Tanemura A, Yang L, Yang F, et al. An immune pathological and ultrastructural skin analysis for rhododenol-induced leukoderma patients. J Dermatol Sci 2015; 77:185.</a></li><li><a class="nounderline abstract_t">Nishioka M, Tanemura A, Yang L, et al. Possible involvement of CCR4+ CD8+ T cells and elevated plasma CCL22 and CCL17 in patients with rhododenol-induced leukoderma. J Dermatol Sci 2015; 77:188.</a></li><li><a class="nounderline abstract_t">Jalalat SZ, Cohen PR. Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation. Dermatol Online J 2013; 19:20020.</a></li><li><a class="nounderline abstract_t">Llamas-Velasco M, Fraga J, Kutzner H, et al. Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study. J Cutan Pathol 2014; 41:417.</a></li><li><a class="nounderline abstract_t">Arya V, Bansal M, Girard L, et al. Vitiligo at Injection Site of PEG-IFN-α 2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review. Case Rep Dermatol 2010; 2:156.</a></li><li><a class="nounderline abstract_t">Oiso N, Sato M, Kawada A. Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C. J Dermatol 2013; 40:772.</a></li><li><a class="nounderline abstract_t">Tolkachjov SN, Comfere NI. Hypopigmented mycosis fungoides: a clinical mimicker of vitiligo. J Drugs Dermatol 2015; 14:193.</a></li><li><a class="nounderline abstract_t">Furlan FC, Sanches JA. Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology. An Bras Dermatol 2013; 88:954.</a></li></ol></div><div id="topicVersionRevision">Topic 105109 Version 15.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25775636" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Low glutathione peroxidase activity levels in patients with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25596811" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25789295" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Highlights in pathogenesis of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25789295" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Highlights in pathogenesis of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25269389" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Stigmatisation, Avoidance Behaviour and Difficulties in Coping are Common Among Adult Patients with Vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24304125" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Quality of life impairment in children and adolescents with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24304125" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Quality of life impairment in children and adolescents with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24304125" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Quality of life impairment in children and adolescents with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24304125" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Quality of life impairment in children and adolescents with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25495880" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Vitiligo treatment update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22417114" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21667529" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Vitiligo: a review of the published work.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12753387" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Epidemiology of vitiligo and associated autoimmune diseases in Caucasian probands and their families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21839315" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Vitiligo: a comprehensive overview Part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22458952" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : A review of the worldwide prevalence of vitiligo in children/adolescents and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25837178" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Prevalence of vitiligo and associated comorbidities in Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35611638" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Vitiligo prevalence and quality of life among adults in Europe, Japan and the USA.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34787670" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prevalence of Vitiligo Among Adults in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37466934" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Incidence and Prevalence of Diagnosed Vitiligo According to Race and Ethnicity, Age, and Sex in the US.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37156255" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37156255" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Incidence, prevalence, and co-occurrence of autoimmune disorders over time and by age, sex, and socioeconomic status: a population-based cohort study of 22 million individuals in the UK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24574898" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Autoimmune complications after hematopoietic stem cell transplantation in children with nonmalignant disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18285686" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Vitiligo after hematopoietic cell transplantation: six cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27836331" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Subsequent vitiligo after hematopoietic stem cell transplantation: A nationwide population-based cohort study from Korea.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10776751" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adoptive transfer of vitiligo after allogeneic bone marrow transplantation for non-Hodgkin's lymphoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25207994" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Risk factors and characterization of vitiligo and alopecia areata in patients with chronic graft-vs-host disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15701915" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : New insights and new therapies in vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11705094" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Vitiligo. Pathogenesis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8162332" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Review of the etiopathomechanism of vitiligo: a convergence theory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1286069" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Genetic nature of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3400640" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A genetical model for vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7977362" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Genetic epidemiology of vitiligo: multilocus recessivity cross-validated.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12707860" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25254010" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Current aspects of vitiligo genetics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15982560" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : HLA associated genetic predisposition to autoimmune diseases: Genes involved and possible mechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1421624" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Vitiligo is associated with a significant increase in HLA-A30, Cw6 and DQw3 and a decrease in C4AQ0 in northern Italian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20410501" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20526339" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Genome-wide association study for vitiligo identifies susceptibility loci at 6q27 and the MHC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22561518" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Genome-wide association analyses identify 13 new susceptibility loci for generalized vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22951725" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Association analyses identify three susceptibility Loci for vitiligo in the Chinese Han population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16098053" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Candidate functional promoter variant in the FOXD3 melanoblast developmental regulator gene in autosomal dominant vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15809929" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : A novel linkage to generalized vitiligo on 4q13-q21 identified in a genomewide linkage analysis of Chinese families.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17377159" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : NALP1 in vitiligo-associated multiple autoimmune disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9591808" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9170158" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Molecular basis of congenital hypopigmentary disorders in humans: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4092795" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Incidence and significance of organ-specific autoimmune disorders (clinical, latent or only autoantibodies) in patients with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6601472" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Autoantibodies and their clinical significance in a black vitiligo population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6196421" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3373009" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Evidence for immunologic mechanisms in human vitiligo: patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12622785" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Evidence for an autoimmune pathogenesis of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2508572" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vitiligo and idiopathic guttate hypomelanosis. Repigmentation of skin following engraftment onto nude mice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3668006" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Natural cell-mediated cytotoxicity in vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9743539" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24238922" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Innate immune mechanisms in vitiligo: danger from within.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19242513" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Autoimmune destruction of skin melanocytes by perilesional T cells from vitiligo patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12925214" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Cytotoxic T lymphocyte reactivity to gp100, MelanA/MART-1, and tyrosinase, in HLA-A2-positive vitiligo patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22860621" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Guidelines for the management of vitiligo: the European Dermatology Forum consensus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16965269" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11676831" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Mitochondrial impairment in peripheral blood mononuclear cells during the active phase of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8751964" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Imbalance in the antioxidant pool in melanoma cells and normal melanocytes from patients with melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1321419" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Catecholamines and vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15009710" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Perturbed 6-tetrahydrobiopterin recycling via decreased dihydropteridine reductase in vitiligo: more evidence for H2O2 stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7599386" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1409425" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : The significance of depigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5528553" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Acquired unilateral vitiligo and poliosis of the head and subacute encephalitis with partial recovery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8647660" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7522512" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Neuropeptide and neuronal marker studies in vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1316387" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Plasma alpha-melanocyte-stimulating hormone, beta-endorphin, met-enkephalin, and natural killer cell activity in vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11641057" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Levels of neuropeptide-Y in the plasma and skin tissue fluids of patients with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12534601" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Melanocyte detachment after skin friction in non lesional skin of patients with generalized vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23252956" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Provoking factors, including chemicals, in Dutch patients with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17250545" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : The definition and assessment of vitiligo: a consensus report of the Vitiligo European Task Force.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21324101" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Koebner's phenomenon in vitiligo: European position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26573093" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Comparison of Childhood Vitiligo Presenting with or without Associated Halo Nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24474125" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Clinical epidemiological profile of vitiligo in children and adolescents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21410675" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Multivariate analysis of factors associated with early-onset segmental and nonsegmental vitiligo: a prospective observational study of 213 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24636650" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Pediatric vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24127636" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Latent class analysis of a series of 717 patients with vitiligo allows the identification of two clinical subtypes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25657420" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Oral manifestations of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25255745" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Hypochromic vitiligo: delineation of a new entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24134308" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : A study of clinical profiles of vitiligo in different ages: an analysis of 669 outpatients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33539593" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : A retrospective analysis of 925 cases of segmental vitiligo in a Chinese Han population.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17420387" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Hypopigmentary fundus changes seen with cutaneous vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15002019" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Cutaneous vitiligo associated with choroidal hypopigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6824621" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Vitiligo and disorders of the retinal pigment epithelium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3722505" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Ocular disturbances in vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/534100" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Ocular abnormalities occurring with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23253044" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24107643" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Comorbidities associated with vitiligo: a ten-year retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22860695" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : The prevalence of thyroid disease in patients with vitiligo: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26518171" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25510261" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Comorbidity profiles in association with vitiligo: a nationwide population-based study in Taiwan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31228523" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : The association between vitiligo and diabetes mellitus: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37405428" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Association of vitiligo with multiple cutaneous and extra-cutaneous autoimmune diseases: a nationwide cross-sectional study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16704638" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23620608" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Clinical phenotypes of autoimmune polyendocrinopathycandidiasis-ectodermal dystrophy seen in the Northern Ireland paediatric population over the last 30 years.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34545845" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Vogt-Koyanagi-Harada disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21099196" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Alezzandrini syndrome: report of a sixth clinical case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14164681" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : [UNILATERAL MANIFESTATIONS OF TAPETO-RETINAL DEGENERATION, VITILIGO, POLIOSIS, GREY HAIR AND HYPOACOUSIA].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7277096" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Kabuki make-up syndrome: a syndrome of mental retardation, unusual facies, large and protruding ears, and postnatal growth deficiency.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15523604" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Autoimmune disorders in Kabuki syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26411453" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Epigenetic control of the immune system: a lesson from Kabuki syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17174051" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Kabuki syndrome with trichrome vitiligo, ectodermal defect and hypogammaglobulinemia A and G.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523781" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Vitiligo-like Depigmentation Associated with Metastatic Melanoma of an Unknown Origin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19878396" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Do we have to pay more attention to vitiligo patients? Peculiar histopathological features of primary cutaneous melanoma preceded by vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18635425" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Images in clinical medicine. Vitiligo and cutaneous melanoma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19622589" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20015281" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Vitiligo is more than skin deep: a survey of members of the Vitiligo Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23974584" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The psychosocial impact of vitiligo in Indian patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20426784" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Vitiligo linked to stigmatization in British South Asian women: a qualitative study of the experiences of living with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19577331" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : The burden of vitiligo: patient characteristics associated with quality of life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28991357" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The prevalence of psychological comorbidity in people with vitiligo: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21668034" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Childhood vitiligo in China: clinical profiles and immunological findings in 620 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18717679" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Impact of childhood vitiligo on adult life.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27328922" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : A Practical Approach to the Diagnosis and Treatment of Vitiligo in Children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25382506" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : The utility of dermoscopy in the diagnosis of evolving lesions of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Application of polarized light dermoscopy in the early diagnosis of vitiligo and its differential diagnosis from other depigmented diseases</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12581146" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Value of histopathology in vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26978003" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinicopathologic Analysis of Stable and Unstable Vitiligo: A Study of 66 Cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20370855" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : First histopathological and immunophenotypic analysis of early dynamic events in a patient with segmental vitiligo associated with halo nevi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16526964" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Anti-thyroid peroxidase antibody and vitiligo: a controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16021113" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Increased prevalence of chronic autoimmune (Hashimoto's) thyroiditis in children and adolescents with vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32274836" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : The necessity of antinuclear antibody investigation in pre-phototherapy vitiligo patients: A retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16298511" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Physiopathology and genetics of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19036036" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Guideline for the diagnosis and management of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25605459" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Possible atomoxetine-induced vitiligo: a case report.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24985165" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Relationship between Helicobacter pylori infection and vitiligo: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26107994" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22417136" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Follicular vitiligo: a new form of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16908347" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Clinical and histopathologic characteristics of nevus depigmentosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9922008" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Nevus depigmentosus: clinical features and histopathologic characteristics in 67 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21699514" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Clinical features of idiopathic guttate hypomelanosis in 646 subjects and association with other aspects of photoaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26146814" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Halo nevus: review of the literature and clinicopathologic findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18782317" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Chemical leucoderma: a clinico-aetiological study of 864 cases in the perspective of a developing country.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22583724" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Chemical leukoderma after the application of a transdermal methylphenidate patch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25676426" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : An immune pathological and ultrastructural skin analysis for rhododenol-induced leukoderma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25766765" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Possible involvement of CCR4+ CD8+ T cells and elevated plasma CCL22 and CCL17 in patients with rhododenol-induced leukoderma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24139363" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Gefitinib-associated vitiligo: report in a man with parotid squamous cell carcinoma and review of drug-induced hypopigmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24467724" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Hypopigmented macules secondary to imatinib for the treatment of chronic myeloid leukemia: a histopathologic and immunohistochemical study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21076689" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Vitiligo at Injection Site of PEG-IFN-α2a in Two Patients with Chronic Hepatitis C: Case Report and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23855823" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Vitiligo after combination therapy of pegylated interferon-α-2a, ribavirin and vitamin D in a patient with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25689815" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Hypopigmented mycosis fungoides: a clinical mimicker of vitiligo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24474105" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Hypopigmented mycosis fungoides: a review of its clinical features and pathophysiology.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
